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Male-to-female ratio was 5:2. In more than 90% of cases, the
pathology was squamous-cell carcinoma. Adenosquamous carci-
noma and adenocarcinomawere less than 10%. Cancers staged as
IV, III, and II made up 38.2%, 53.7%, and 10.1% of cases, respec-
tively, and 23.6% of cases involved metastasis. 22 patients
(2.63%) had adverse reactions that were unlikely to be due to nim-
otuzumab, including chills and fever in eight cases (0.96%), rash
in five cases (0.6%), oral mucositis in three cases (0.36%), gastroin-
testinal symptoms (vomiting or diarrhoea) in two cases (0.24%),
and dizziness in one case (0.12%). One patient had significant fati-
gue (0.12%), five had thrombocytopenia (0.6%), and five had
decreased white blood-cell count. Nimotuzumab-induced allergy
occurred in one case (0.12%).
Interpretation: Nimotuzumab combined with chemotherapy,
radiotherapy, or chemoradiotherapy for patients with advanced
carcinoma is well tolerated and safe.
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Background: We evaluated clinical outcomes and acute toxicity
in nasopharyngeal carcinoma treated with tomotherapy followed
by anti-EGFR monoclonal antibodies.
Methods: Between March, 2008, and November, 2009, 34
patients with newly diagnosed nasopharyngeal carcinoma were
treated with helical tomotherapy combined with nimotuzumab
(group N) or cetuximab (group C). All patients received tomother-
apy at 70 Gy/33F for the gross tumour volume (pGTVnx) and posi-
tive lymph nodes (GTVnd), 60Gy/33F for the high-risk clinical
target volume (CTV1), and 56 Gy/33F for the low-risk clinical tar-
get volume (CTV2). 17 patients in group N were given a weekly
injection of 200 mg/m2 for 6–7 weeks, and 17 patients in group
C were given an initial intravenous dose of 400 mg/m2 in the first
week, followed by weekly injections of 250 mg/m2 for 6–7 weeks.
Acute lesions were evaluated with the RTOG/EORTC criteria.
Findings The median follow-up was 22 months. Effective rates
(complete + partial responses) at 3, 6, and 12 months were 82.4%
(14/17), 70.6% (12/17), and 70.6% (12/17) in group N, and 88.2%
(15/17), 82.4% (14/17), and 82.4% (14/17) in group C. 1-year survival
was 88.2% (15/17) in group N and 100% (17/17) in group C. Nim-
otuzumab was associated with less acute mucositis (u = 2.245,
p < 0.05), weight loss (t 0 = 2.563, p = 0.0153) and rash (u = 4.362,
p < 0.01) than cetuximab.
Interpretation: Helical tomotherapy combined with nim-
otuzumab or cetuximab was effective for nasopharyngeal
carcinoma, and there was no difference in short-term efficacy
or 1-year survival. Nimotuzumab has fewer acute reactions than
cetuximab. More studies should be done to ascertain the long-
term effects.
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Background: We explored the efficacy of biological targeted
therapy combined with chemotherapy.
Methods: 71 patients (54 men and 17 women; age 30–83 years,
mean 60) were enrolled in this study. All patients had locally
advanced oral-maxillofacial and head and neck tumours (no indi-
cation for surgery or radiotherapy) confirmed by histology and
radiology, with indication for biochemotherapy. The chemother-
apy regimen given was cisplatin 75 mg/m2 day 1, paclitaxel
75 mg/m2 day 1, fluorouracil 750 mg/m2 days 1–5, and nim-
otuzumab 200 mg/m2 weekly.
Findings: Patients completed 2–4 cycles of chemotherapy
(mean 2.2). Nimotuzumab was given 2–8 times (mean 4.3). The
prognosis was as follows: complete response in four patients, par-
tial response in 39, stable disease in 18, and progressive disease in
3. Seven patients could not be evaluated. The total effective rate,
calculated as complete plus partial responses, was 61%. 29
patients had surgery after biochemotherapy. No serious adverse
reactions were noted during the course of the treatment, only
one case of slight erythra infection.
Interpretation: Nimotuzumab was effective in increasing
chemosensitivity and had a good tolerability profile.
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